Detalles de la búsqueda
1.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat;
199(2): 371-379, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36988749
2.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol;
23(11): 1367-1377, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36183733
3.
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.
Anal Chem;
94(16): 6297-6303, 2022 04 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35416669
4.
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Future Oncol;
18(22): 2383-2392, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695563
5.
Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Breast Cancer Res;
22(1): 36, 2020 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32295625
6.
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Breast Cancer Res Treat;
179(2): 387-401, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31620934
7.
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.
Breast Cancer Res;
21(1): 65, 2019 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31101122
8.
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Int J Cancer;
143(8): 2053-2064, 2018 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29756206
9.
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.
Br J Cancer;
119(3): 303-312, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30013091
10.
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Int J Colorectal Dis;
32(8): 1179-1190, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424871
11.
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
N Engl J Med;
369(11): 1023-34, 2013 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24024839
12.
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Breast Cancer Res Treat;
156(2): 301-10, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26975189
13.
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Breast Cancer Res Treat;
156(2): 319-30, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26993131
14.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Breast Cancer Res;
16(6): 466, 2014 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-25416589
15.
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial.
EBioMedicine;
104: 105141, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38718683
16.
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.
Breast Cancer Res Treat;
139(3): 789-800, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23780683
17.
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Ann Surg Oncol;
20 Suppl 3: S650-60, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23884751
18.
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
J Clin Oncol;
41(36): 5569-5578, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751561
19.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nat Commun;
14(1): 7018, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37919269
20.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Oncologist;
17(7): 900-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22610153